These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 32826103)
1. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development. Grady C; Shah S; Miller F; Danis M; Nicolini M; Ochoa J; Taylor H; Wendler D; Rid A Vaccine; 2020 Sep; 38(41):6381-6387. PubMed ID: 32826103 [TBL] [Abstract][Full Text] [Related]
2. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies? Schaefer GO; Tam CC; Savulescu J; Voo TC Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271 [TBL] [Abstract][Full Text] [Related]
4. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771 [TBL] [Abstract][Full Text] [Related]
5. Vaccine Against Covid-19 Disease - Present Status of Development. Dutta AK Indian J Pediatr; 2020 Oct; 87(10):810-816. PubMed ID: 32880819 [TBL] [Abstract][Full Text] [Related]
7. From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons? Hanney SR; Wooding S; Sussex J; Grant J Health Res Policy Syst; 2020 Jun; 18(1):61. PubMed ID: 32513202 [TBL] [Abstract][Full Text] [Related]
8. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. Eyal N; Lipsitch M; Smith PG J Infect Dis; 2020 May; 221(11):1752-1756. PubMed ID: 32232474 [TBL] [Abstract][Full Text] [Related]
9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409 [TBL] [Abstract][Full Text] [Related]
10. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Calina D; Sarkar C; Arsene AL; Salehi B; Docea AO; Mondal M; Islam MT; Zali A; Sharifi-Rad J Immunol Res; 2020 Dec; 68(6):315-324. PubMed ID: 33006053 [TBL] [Abstract][Full Text] [Related]
11. Human Infection Challenge Studies: a Test for the Social Value Criterion of Research Ethics. Evans NG mSphere; 2020 Jul; 5(4):. PubMed ID: 32669462 [TBL] [Abstract][Full Text] [Related]
12. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494 [TBL] [Abstract][Full Text] [Related]
13. Coronavirus Vaccine: Light at the End of the Tunnel. Ella KM; Mohan VK Indian Pediatr; 2020 May; 57(5):407-410. PubMed ID: 32291382 [TBL] [Abstract][Full Text] [Related]
14. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues. Baay M; Neels P Biologicals; 2020 Sep; 67():69-74. PubMed ID: 32829985 [TBL] [Abstract][Full Text] [Related]
16. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial. Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170 [TBL] [Abstract][Full Text] [Related]
17. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505 [TBL] [Abstract][Full Text] [Related]
18. Developing Covid-19 Vaccines at Pandemic Speed. Lurie N; Saville M; Hatchett R; Halton J N Engl J Med; 2020 May; 382(21):1969-1973. PubMed ID: 32227757 [No Abstract] [Full Text] [Related]
19. Understanding COVID-19 vaccine efficacy. Lipsitch M; Dean NE Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460 [No Abstract] [Full Text] [Related]
20. A vaccine is not too far for COVID-19. Patel SK; Pathak M; Tiwari R; Yatoo MI; Malik YS; Sah R; Rabaan AA; Sharun K; Dhama K; Bonilla-Aldana DK; Rodriguez-Morales AJ J Infect Dev Ctries; 2020 May; 14(5):450-453. PubMed ID: 32525830 [No Abstract] [Full Text] [Related] [Next] [New Search]